Butorphanol as an Adjuvant to Ropivacaine for Adductor Canal Blocks in Total Knee Arthroplasty .
Butorphanol as an Adjuvant to Ropivacaine for Adductor Canal Blocks in Total Knee Arthroplasty Patients: A Randomized, Double, Blind Study
J Healthc Eng. 2022 Oct 14;2022:7718108.Seventy-four older patients (50-80 years) undergoing a first-time unilateral total knee arthroplasty were randomized to receive an adductor canal blockade with ropivacaine plus butorphanol as an adjuvant (n=37) or ropivacaine only (n=37). The primary outcome of interest was the duration of sensory block and Visual Analog Scale (VAS) pain scores at rest and with activity. Secondary outcomes of interest included patient-controlled analgesia demand, quadriceps strength, knee range of motion, time to first mobilization, Knee Society Score (KSS) function score at discharge, length of stay, and post-operative complications. The results found significantly longer sensory blockade, better knee range of motion and lower VAS pain scores in the early postoperative period, and lower demand for patient-controlled analgesia with adjuvant butorphanol vs. control. No differences in quadriceps muscle strength, time to mobilization, KSS function scores, length of stay or complications were observed between groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics